DMI019
/ Jiangsu Demai Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 23, 2026
This Phase 1a Study Will Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Relative Bioavailability of Single-dose DMI019 Nasal Spray in Healthy Participants.
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: The Third Xiangya Hospital of Central South University
New P1 trial
1 to 1
Of
1
Go to page
1